

Resource Summary Report

Generated by T1D on Aug 2, 2026

Genomics of Drug Sensitivity in Cancer

RRID:SCR_011956

Type: Tool

Proper Citation

Genomics of Drug Sensitivity in Cancer (RRID:SCR_011956)

Resource Information

URL: <http://www.cancerrxgene.org/>

Proper Citation: Genomics of Drug Sensitivity in Cancer (RRID:SCR_011956)

Description: A genomics database project is an academic research program to identify molecular features of cancers that predict response to anti-cancer drugs.

Abbreviations: Genomics of Drug Sensitivity in Cancer

Resource Type: database, data or information resource

Keywords: compound, gene, molecule, drug, FASEB list

Related Condition: Cancer

Funding: Wellcome Trust

Resource Name: Genomics of Drug Sensitivity in Cancer

Resource ID: SCR_011956

Alternate IDs: OMICS_01581

Record Creation Time: 20220129T080307+0000

Record Last Update: 20260803T040556+0000

Ratings and Alerts

No rating or validation information has been found for Genomics of Drug Sensitivity in Cancer.

No alerts have been found for Genomics of Drug Sensitivity in Cancer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1418 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Luan R, et al. (2026) Pan-cancer multi-omics reveals DCAF7 as an immune-modulating prognostic driver and Wnt/ β -catenin activator in hepatocellular carcinoma. *Clinical and translational medicine*, 16(1), e70572.

Wen Q, et al. (2026) Identification and Validation of the Prognostic Value of PTTG1-Related Genes in Hepatocellular Carcinoma by Mendelian Randomization and Single-Cell Transcriptome Analysis. *Iranian journal of biotechnology*, 24(1), e4221.

Luo M, et al. (2025) Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations. *Cancer discovery*, 15(3), 511.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. *Cancer research communications*, 5(2), 375.

Tian P, et al. (2025) scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(2), e2412419.

Chi S, et al. (2025) BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair. *Translational oncology*, 51, 102212.

Zhao X, et al. (2025) CXCL8 modulates M0 macrophage proliferation and polarization to influence tumor progression in cervical cancer. *Scientific reports*, 15(1), 790.

Wu Y, et al. (2025) Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma. *Scientific reports*, 15(1), 954.

Chen Z, et al. (2025) Orchestrated desaturation reprogramming from stearyl-CoA desaturase to fatty acid desaturase 2 in cancer epithelial-mesenchymal transition and metastasis. *Cancer communications (London, England)*, 45(3), 245.

Zhang XJ, et al. (2025) Improving molecular subtypes and prognosis of pancreatic cancer through multi group analysis and machine learning. *Discover oncology*, 16(1), 96.

Yang YC, et al. (2025) GNE-317 Reverses MSN-Mediated Proneural-to-Mesenchymal Transition and Suppresses Chemoradiotherapy Resistance in Glioblastoma via PI3K/mTOR. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(12), e2412517.

Chen G, et al. (2025) Development and Validation of Prognostic Characteristics Associated With Chromatin Remodeling-Related Genes in Ovarian Cancer. *Cancer medicine*, 14(3), e70634.

Zhang H, et al. (2025) UBC9: a novel therapeutic target in papillary thyroid carcinoma. *Journal of endocrinological investigation*, 48(5), 1101.

Chen L, et al. (2025) Exploring NUP62's role in cancer progression, tumor immunity, and treatment response: insights from multi-omics analysis. *Frontiers in immunology*, 16, 1559396.

Wang B, et al. (2025) Development and validation of M2 macrophage-related genes in a prognostic model of lung adenocarcinoma based on bulk RNA and ScRNA datasets. *Discover oncology*, 16(1), 352.

Mirghani AH, et al. (2025) Synthesis and Characterization of Schiff Bases and Their Ag(I) Complexes Containing 2,5,6-Trisubstituted Imidazothiadiazole Derivatives: Molecular Docking and In Vitro Cytotoxic Effects Against Nonsmall Lung Cancer Cell Line. *Journal of biochemical and molecular toxicology*, 39(2), e70142.

Chen Z, et al. (2025) RBIS as a prognostic biomarker for progression-free survival in prostate cancer: insights from bioinformatics and immune infiltration analysis. *Discover oncology*, 16(1), 297.

Codicè F, et al. (2025) The specification game: rethinking the evaluation of drug response prediction for precision oncology. *Journal of cheminformatics*, 17(1), 33.

Wang Y, et al. (2025) Role of arachidonic acid metabolism in osteosarcoma prognosis by integrating WGCNA and bioinformatics analysis. *BMC cancer*, 25(1), 445.

Huang W, et al. (2025) An Anti-CD147 Antibody-Drug Conjugate Mehozumab-DM1 is Efficacious Against Hepatocellular Carcinoma in Cynomolgus Monkey. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(15), e2410438.